Breast Biopsy Devices Market Report with Top Key Players, Types, and Application
Global breast biopsy devices market is forecasted to generate a revenue of $1.4 billion by 2023, P&S Market Research.
By: P&S Intelligence
On the basis of the procedure conducted for breast biopsy (https://www.psmarketresearch.com/
During the forecast period, the breast biopsy devices industry is expected to witness the fastest growth in in Asia-Pacific (APAC), owing to growing geriatric population, increasing prevalence of breast cancer, growing awareness about breast cancer, rising healthcare expenditure, per capita income, and increasing research in breast biopsy devices in the region. According to National Institute of Cancer Prevention and Research, breast cancer is the most common cancer in women in India and accounts for about a quarter of all cancers in women in Indian cities, and the average age for breast cancer in India is almost a decade lower than that in the West.
In August 2017, Hologic Inc. announced the commercial availability of Brevera breast biopsy system with CorLumina imaging technology, in the U.S. The Brevera system provides clinicians with more information at the point of care and results in significant cost and time savings without compromising with accuracy or patient health outcomes.
Some of the other major players operating in the breast biopsy devices market include Danaher Corporation, Argon Medical Devices Inc., Becton, Dickinson and Company, Sterylab S.R.L., Scion Medical Technologies LLC, Planmed Oy, Medtronic plc, and Cook Medical LLC.